# Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

> **NCT04147650** · PHASE2,PHASE3 · COMPLETED · sponsor: **Aurinia Pharmaceuticals Inc.** · enrollment: 508 (actual)

## Conditions studied

- Dry Eye Syndrome
- Keratoconjunctivitis Sicca

## Interventions

- **DRUG:** 0.05% Voclosporin Ophthalmic Solution (VOS)
- **DRUG:** 0.10% VOS
- **DRUG:** 0.20% VOS
- **DRUG:** Vehicle Ophthalmic Solution

## Key facts

- **NCT ID:** NCT04147650
- **Lead sponsor:** Aurinia Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-14
- **Primary completion:** 2020-09-17
- **Final completion:** 2020-10-08
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2021-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04147650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04147650, "Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04147650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*